The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Interactions of Transforming Growth Factor-β and Angiotensin II in Renal Fibrosis
Open accessAbstract
Overproduction of transforming growth factor-β clearly underlies tissue fibrosis in numerous experimental and human diseases. Transforming growth factor-β’s powerful fibrogenic action results from simultaneous stimulation of matrix protein synthesis, inhibition of matrix degradation, and enhanced integrin expression that facilitates matrix assembly. In animals, overexpression of transforming growth factor-β by intravenous injection, transient gene transfer, or transgene insertion has shown that the kidney is highly susceptible to rapid fibrosis. The same seems true in human disease, where excessive transforming growth factor-β has been demonstrated in glomerulonephritis, diabetic nephropathy, and hypertensive glomerular injury. A possible explanation for the kidney’s particular susceptibility to fibrosis may be the recent discovery of biologically complex interactions between the renin-angiotensin system and transforming growth factor-β. Alterations in glomerular hemodynamics can activate both the renin-angiotensin system and transforming growth factor-β. Components of the renin-angiotensin system act to further stimulate production of transforming growth factor-β and plasminogen activator inhibitor leading to rapid matrix accumulation. In volume depletion, transforming growth factor-β is released from juxtaglomerular cells and may act synergistically with angiotensin II to accentuate vasoconstriction and acute renal failure. Interaction of the renin-angiotensin system and transforming growth factor-β has important clinical implications. The protective effect of inhibition of the renin-angiotensin system in experimental and human kidney diseases correlates closely with the suppression of transforming growth factor-β production. This suggests that transforming growth factor-β, in addition to blood pressure, should be a therapeutic target. Higher doses or different combinations of drugs that block the renin-angiotensin system or entirely new drug strategies may be needed to achieve a greater antifibrotic effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Transforming Growth Factor β in Tissue Fibrosis
Epstein, F. H., Border, W. A., & Noble, N. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311907 · Cited by 3,069
Self-citationKagami, S., Border, W. A., Miller, D. E., & Noble, N. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117251 · Cited by 1,076
Self-citationControl of glomerular hypertension limits glomerular injury in rats with reduced renal mass.
Anderson, S., Meyer, T. W., Rennke, H. G., & Brenner, B. M. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112013 · Cited by 932
Cell-Associated Plasminogen Activation: Regulation and Physiological Functions
Saksela, O., & Rifkin, D. B. (1988) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.04.110188.000521 · Cited by 818
Sanderson, N., Factor, V, Nagy, P., Kopp, J., Kondaiah, P., Wakefield, L., Roberts, A. B., Sporn, M. B., & Thorgeirsson, S. S. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2572 · Cited by 671
Gibbons, G. H., Pratt, R. E., & Dzau, V. J. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115881 · Cited by 645
Impaired wound healing in mice with a disrupted plasminogen gene
Rømer, J., Bugge, T. H., Fyke, C., Lund, L. R., Flick, M. J., Degen, J. L., & Danø, K. (1996) · Nature Medicine · doi:10.1038/nm0396-287 · Cited by 561
Eitzman, D. T., McCoy, R. D., Zheng, X., Fay, W. P., Shen, T., Ginsburg, D., & Simon, R. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118396 · Cited by 558
Vaughan, D. E., Lazos, S. A., & Tong, K. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117809 · Cited by 530
Cited by
Safian, R. D., & Textor, S. C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102083440607 · Cited by 1,068
Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases
Kim, S., & Iwao, H. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01434-0 · Cited by 983
Vascular Remodeling in Hypertension: Roles of Apoptosis, Inflammation, and Fibrosis
Intengan, H. D., & Schiffrin, E. L. (2001) · Hypertension · doi:10.1161/hy09t1.096249 · Cited by 979
Touyz, R. M., & Schiffrin, E. L. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01471-6 · Cited by 934
Mechanisms of Tubulointerstitial Fibrosis
Zeisberg, M., & Neilson, E. G. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010080793 · Cited by 868
Yang, J., & Liu, Y. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62533-3 · Cited by 751
Inflammation and angiotensin II
Suzuki, Y., Ruiz-Ortega, M., Lorenzo, O., Ruperez, M., Esteban, V., & Egido, J. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(02)00271-6 · Cited by 694
Angiotensin II and Renal Fibrosis
Mezzano, S. A., Ruiz-Ortega, M., & Egido, J. (2001) · Hypertension · doi:10.1161/hy09t1.094234 · Cited by 523
Angiotensin II induces contraction and proliferation of human hepatic stellate cells
Bataller, R., Ginès, P., Nicolás, J. M., Görbig, M. N., Garcia–Ramallo, E., Gasull, X., Bosch, J., Arroyo, V., & Rodés, J. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70368-4 · Cited by 490
Induction of Cardiac Fibrosis by Transforming Growth Factor-β1
Lijnen, P. J., Petrov, V. V., & Fagard, R. H. (2000) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2000.3032 · Cited by 464
COVID-19 cytokine storm: the anger of inflammation
Mahmudpour, M., Roozbeh, J., Keshavarz, M., Farrokhi, S., & Nabipour, I. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155151 · Cited by 461
Huang, Y., Wongamorntham, S., Kasting, J., McQuillan, D., Owens, R. T., Yu, L., Noble, N. A., & Border, W. (2006) · Kidney International · doi:10.1038/sj.ki.5000011 · Cited by 423
Self-citationProinflammatory actions of angiotensins
Ruiz-Ortega, M., Lorenzo, O., Suzuki, Y., Rupérez, M., & Egido, J. (2001) · Current Opinion in Nephrology and Hypertension · doi:10.1097/00041552-200105000-00005 · Cited by 412
NOGUEIRA, A., PIRES, M. J., & OLIVEIRA, P. A. (2017) · In Vivo · doi:10.21873/invivo.11019 · Cited by 382
Hepatocyte growth factor: Renotropic role and potential therapeutics for renal diseases
Matsumoto, K., & Nakamura, T. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00717.x · Cited by 353
Lv, W., Booz, G. W., Wang, Y., Fan, F., & Roman, R. J. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.12.016 · Cited by 338
Rodríguez-Vita, J., Sánchez-López, E., Esteban, V., Rupérez, M., Egido, J., & Ruiz-Ortega, M. (2005) · Circulation · doi:10.1161/01.cir.0000165133.84978.e2 · Cited by 327
Yang, J., & Liu, Y. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v13196 · Cited by 326
Renovascular Hypertension and Ischemic Nephropathy
Garovic, V. D., & Textor, S. C. (2005) · Circulation · doi:10.1161/circulationaha.104.492348 · Cited by 296
Wolf, G. (2006) · Kidney International · doi:10.1038/sj.ki.5001846 · Cited by 292
Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers
Twigg, S. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1991 · Cited by 286
Feldman, D. L., Jin, L., Xuan, H., Contrepas, A., Zhou, Y., Webb, R. L., Mueller, D. N., Feldt, S., Cumin, F., Maniara, W., et al. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.108845 · Cited by 283
Suthanthiran, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050420897 · Cited by 281
Vascular Remodeling in Hypertension: Mechanisms and Treatment
Schiffrin, E. L. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.187021 · Cited by 276
Is obesity a major cause of chronic kidney disease?
Hall, J. E., Henegar, J. R., Dwyer, T. M., Liu, J., da Silva, A. A., Kuo, J. J., & Tallam, L. (2004) · Advances in Renal Replacement Therapy · doi:10.1053/j.arrt.2003.10.007 · Cited by 264
Connective Tissue Growth Factor Is a Mediator of Angiotensin II–Induced Fibrosis
Rupérez, M., Lorenzo, O., Blanco-Colio, L. M., Esteban, V., Egido, J., & Ruiz-Ortega, M. (2003) · Circulation · doi:10.1161/01.cir.0000089129.51288.ba · Cited by 267
Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action
Liu, Y. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00451.2003 · Cited by 265
Pathophysiology of the Diabetic Kidney
Vallon, V., & Komers, R. (2011) · Comprehensive Physiology · doi:10.1002/cphy.c100049 · Cited by 259
Dzau, V. J., Bernstein, K., Celermajer, D., Cohen, J., Dahlöf, B., Deanfield, J., Diez, J., Drexler, H., Ferrari, R., van Gilst, W., et al. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01878-1 · Cited by 259
Yang, F., Chung, A. C. K., Huang, X. R., & Lan, H. Y. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.136531 · Cited by 258
Chen, S., Jim, B., & Ziyadeh, F. N. (2003) · Seminars in Nephrology · doi:10.1053/s0270-9295(03)00132-3 · Cited by 256
αvβ6 Integrin Regulates Renal Fibrosis and Inflammation in Alport Mouse
Hahm, K., Lukashev, M. E., Luo, Y., Yang, W. J., Dolinski, B. M., Weinreb, P. H., Simon, K. J., Chun Wang, L., Leone, D. R., Lobb, R. R., et al. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060158 · Cited by 190
Angiotensin II Activates Collagen I Gene Through a Mechanism Involving the MAP/ER Kinase Pathway
Tharaux, P.-L., Chatziantoniou, C., Fakhouri, F., & Dussaule, J.-C. (2000) · Hypertension · doi:10.1161/01.hyp.36.3.330 · Cited by 173
González-Abraldes, J., Albillos, A., Bañares, R., Del Arbol, L. R., Moitinho, E., Rodríguez, C., González, M., Escorsell, A., García-Pagán, J. C., & Bosch, J. (2001) · Gastroenterology · doi:10.1053/gast.2001.26288 · Cited by 165
Metadata
- Authors
- Border, W. A., & Noble, N. A.
- Venue
- Hypertension
- Published
- 1998-01
- Volume
- 31
- Issue
- 1
- Pages
- 181-188
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2128520582
- Cited by
- 447
- References
- 54
- FWCI
- 23.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.